Coltsfoot Leaf (Tussilago farfara)

Coltsfoot leaf (Tussilago farfara) contains key bioactives including tussilagone, flavonoids such as quercetin and kaempferol, and phenolic acids like chlorogenic acid. These compounds exhibit antimicrobial, anti-inflammatory, and antioxidant activity primarily through inhibition of pro-inflammatory mediators and free radical scavenging in preclinical models.

Origin & History

Coltsfoot leaf comes from the Tussilago farfara plant, a perennial herb native to Europe, Asia, and parts of North America. The leaves are harvested post-flowering and typically dried for use, with active compounds extracted via hydroalcoholic or methanolic methods.

Historical & Cultural Context

Coltsfoot leaf has been traditionally used in European herbalism and Asian systems like Traditional Chinese Medicine for treating coughs, respiratory issues, and inflammation. Historical applications also include diabetes and as a uterine stimulant.

Health Benefits

• Exhibits antimicrobial activity against gram-negative bacteria (preclinical studies).[2] • Contains flavonoids with potential anti-inflammatory properties (inferred from phytochemistry).[1][2] • May provide antioxidant effects through phenolic acids (preclinical evidence).[1][4] • Historical use suggests benefits for respiratory issues and cough treatment (traditional use).[1][3][5] • Potential to modulate inflammation via sesquiterpenes (preclinical studies).[3]

How It Works

Tussilagone, a sesquiterpene ester found in coltsfoot, has been shown to inhibit platelet-activating factor (PAF) receptors and suppress NF-κB signaling, reducing downstream production of pro-inflammatory cytokines such as TNF-α and IL-6. Flavonoids including quercetin and kaempferol inhibit cyclooxygenase (COX) enzymes and lipoxygenase (LOX) pathways, dampening prostaglandin and leukotriene synthesis. Chlorogenic acid and other phenolic acids scavenge reactive oxygen species (ROS) and chelate metal ions, contributing to the observed antioxidant activity in cell-based assays.

Scientific Research

No key human clinical trials or meta-analyses are available for coltsfoot leaf. Research is limited to preclinical studies on its phytochemistry and in vitro effects. No PubMed PMIDs are reported for RCTs.

Clinical Summary

The evidence base for coltsfoot leaf in humans is extremely limited, with no well-designed randomized controlled trials establishing efficacy for any indication. Most available data derives from in vitro cell studies and small animal models demonstrating antimicrobial effects against gram-negative bacteria and anti-inflammatory activity. Traditional ethnobotanical use across European and Asian cultures for respiratory complaints, including coughs and bronchitis, predates modern clinical investigation but does not substitute for controlled evidence. The herb's pyrrolizidine alkaloid (PA) content, particularly senkirkine and senecionine, has prompted regulatory restrictions in multiple countries, making formal human trials ethically complex.

Nutritional Profile

Coltsfoot leaf (Tussilago farfara) is not a significant dietary source of macronutrients but contains a range of bioactive phytochemicals. Moisture content in fresh leaves is approximately 80–85%. Dried leaf material contains modest fiber (~10–15% by dry weight), minimal protein (~5–8% dry weight), and negligible fat. Key bioactive compounds include: (1) Pyrrolizidine alkaloids (PAs) — senkirkine and senecionine are the primary hepatotoxic PAs, typically present at 0.015–0.06 mg/g in dried leaf material, with concentrations varying significantly by plant part and growth stage (flowers and roots contain higher levels than leaves); bioavailability is high via oral route with first-pass hepatic metabolism generating toxic pyrrole intermediates. (2) Flavonoids — quercetin, kaempferol, and their glycosides (rutin, hyperoside) present at approximately 0.5–1.5% dry weight; isorhamnetin glycosides also identified; moderate bioavailability enhanced by gut microbial deglycosylation. (3) Phenolic acids — caffeic acid, chlorogenic acid, and 3,5-dicaffeoylquinic acid (cynarin-like compounds) at roughly 1–3% dry weight; chlorogenic acid estimated at 0.8–2.0 mg/g dried leaf; moderate bioavailability via passive absorption in small intestine. (4) Mucilaginous polysaccharides — polysaccharide fraction comprising arabinogalactans and fructans at approximately 7–8% dry weight; these contribute to demulcent/soothing properties; limited systemic bioavailability but locally active in mucous membranes. (5) Terpenes and sterols — tussilagone (a sesquiterpene) identified as a key active compound; sitosterol and other phytosterols present in minor amounts (<0.1% dry weight). (6) Minerals — potassium is the predominant mineral (~15–20 mg/g dry weight), followed by calcium (~8–12 mg/g), magnesium (~2–4 mg/g), and zinc in trace amounts; iron content approximately 0.1–0.3 mg/g dry weight. (7) Vitamins — vitamin C reported at approximately 5–15 mg/100 g fresh weight; traces of vitamin E (tocopherols) present but not at nutritionally significant levels. (8) Tannins — approximately 5% dry weight, primarily hydrolyzable tannins, contributing to astringent properties with limited systemic absorption. Overall nutritional contribution as a food source is negligible; the plant is used primarily for its phytochemical bioactivity. The presence of hepatotoxic PAs significantly limits safe consumption, and many regulatory bodies (e.g., German Commission E, HMPC/EMA) restrict or advise against internal use of PA-containing preparations.

Preparation & Dosage

No clinically studied dosage ranges are available due to the lack of human trials. Traditional use lacks standardization details. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Elderberry, Echinacea, Licorice Root, Mullein, Marshmallow Root

Safety & Interactions

Coltsfoot leaf contains hepatotoxic pyrrolizidine alkaloids (PAs), specifically senkirkine and senecionine, which are metabolized by hepatic CYP3A4 enzymes into toxic pyrrole derivatives capable of causing veno-occlusive liver disease with chronic exposure. It is contraindicated in pregnancy and lactation due to potential embryotoxic and genotoxic effects of PAs, and should be avoided in individuals with pre-existing liver disease or those taking hepatotoxic medications. Potential interactions exist with anticoagulants such as warfarin, as tussilagone's PAF-inhibiting activity may potentiate bleeding risk. Germany's Commission E and the European Medicines Agency have restricted or advised against internal use of PA-containing coltsfoot preparations, and products should be PA-free if used at all.